BibTex RIS Kaynak Göster

Sudden death in athletes Rewiev

Yıl 2006, Cilt: 41 Sayı: 3, 131 - 138, 01.09.2006

Figen Akalın

Öz

-

Anahtar Kelimeler

-

Kaynakça

  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
  • Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48.
  • Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30.
  • Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804.
  • Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
  • Luckstead EF. Cardiac risk factors and participation guidelines
  • for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
  • Germann CA, Perron AD. Sudden cardiac death in athletes:
  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92. 11. Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
  • Luckstead EF. Cardiac risk factors and participation guidelines
  • for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
  • Germann CA, Perron AD. Sudden cardiac death in athletes:
  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
  • Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
  • Luckstead EF. Cardiac risk factors and participation guidelines
  • for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
  • Germann CA, Perron AD. Sudden cardiac death in athletes:
  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: re commendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
  • Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitli n MD, Douglas P S, Parmley WW. 26th Bethesd a Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8.

Sporcularda ani ölüm Derleme

Yıl 2006, Cilt: 41 Sayı: 3, 131 - 138, 01.09.2006

Figen Akalın

Öz

bir öykü, aile öyküsü ve fizik muayenenin yanısıra elektrokardiyografi ile değerlendirme birçok kalp hastalığının dışlanmasını sağlayacaktır

Anahtar Kelimeler

ani ölüm spor ölümleri sporcu kalbi

Kaynakça

  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
  • Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48.
  • Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30.
  • Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804.
  • Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
  • Luckstead EF. Cardiac risk factors and participation guidelines
  • for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
  • Germann CA, Perron AD. Sudden cardiac death in athletes:
  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92. 11. Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
  • Luckstead EF. Cardiac risk factors and participation guidelines
  • for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
  • Germann CA, Perron AD. Sudden cardiac death in athletes:
  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
  • Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
  • Luckstead EF. Cardiac risk factors and participation guidelines
  • for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
  • Germann CA, Perron AD. Sudden cardiac death in athletes:
  • Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: re commendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
  • Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
  • Cheitli n MD, Douglas P S, Parmley WW. 26th Bethesd a Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
  • Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
  • Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
  • Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
  • Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
  • Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
  • Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
  • Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
  • Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
  • Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
  • Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
  • Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
  • Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
  • Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
  • Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
  • Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
  • Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
  • Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
  • Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8.
Toplam 95 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Derleme
Yazarlar

Figen Akalın Bu kişi benim

Yayımlanma Tarihi 1 Eylül 2006
Yayımlandığı Sayı Yıl 2006 Cilt: 41 Sayı: 3

Kaynak Göster

APA Akalın, F. (2006). Sporcularda ani ölüm Derleme. Türk Pediatri Arşivi, 41(3), 131-138.
AMA Akalın F. Sporcularda ani ölüm Derleme. Türk Pediatri Arşivi. Eylül 2006;41(3):131-138.
Chicago Akalın, Figen. “Sporcularda Ani ölüm Derleme”. Türk Pediatri Arşivi 41, sy. 3 (Eylül 2006): 131-38.
EndNote Akalın F (01 Eylül 2006) Sporcularda ani ölüm Derleme. Türk Pediatri Arşivi 41 3 131–138.
IEEE F. Akalın, “Sporcularda ani ölüm Derleme”, Türk Pediatri Arşivi, c. 41, sy. 3, ss. 131–138, 2006.
ISNAD Akalın, Figen. “Sporcularda Ani ölüm Derleme”. Türk Pediatri Arşivi 41/3 (Eylül 2006), 131-138.
JAMA Akalın F. Sporcularda ani ölüm Derleme. Türk Pediatri Arşivi. 2006;41:131–138.
MLA Akalın, Figen. “Sporcularda Ani ölüm Derleme”. Türk Pediatri Arşivi, c. 41, sy. 3, 2006, ss. 131-8.
Vancouver Akalın F. Sporcularda ani ölüm Derleme. Türk Pediatri Arşivi. 2006;41(3):131-8.